The DNA methylation landscape of hematological malignancies: an update
| Autor: | Blecua, Pedro, Martínez-Verbo, Laura, Esteller, M., Universitat Autònoma de Barcelona |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research Limfomes Lymphoma Disease Review Epigenesis Genetic 0302 clinical medicine Càncer Cancer Hematology Leukemia hematology leukemia Leucèmia General Medicine Methylation lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Prognosis Oncology 030220 oncology & carcinogenesis Hematologic Neoplasms DNA methylation Molecular Medicine Epigenetics Lymphomas Immunotherapy Metilació medicine.medical_specialty lymphoma Biology lcsh:RC254-282 03 medical and health sciences Internal medicine Genetics medicine Animals Humans cancer Hematologia epigenetics Myelodysplastic syndromes DNA Methylation medicine.disease Epigenètica Hematopoiesis 030104 developmental biology Cancer research methylation |
| Zdroj: | Dipòsit Digital de la UB Universidad de Barcelona Dipòsit Digital de Documents de la UAB Universitat Autònoma de Barcelona Recercat. Dipósit de la Recerca de Catalunya instname Molecular Oncology Recercat: Dipósit de la Recerca de Catalunya Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya) Molecular Oncology, Vol 14, Iss 8, Pp 1616-1639 (2020) |
| Popis: | The rapid advances in high‐throughput sequencing technologies have made it more evident that epigenetic modifications orchestrate a plethora of complex biological processes. During the last decade, we have gained significant knowledge about a wide range of epigenetic changes that crucially contribute to some of the most aggressive forms of leukemia, lymphoma, and myelodysplastic syndromes. DNA methylation is a key epigenetic player in the abnormal initiation, development, and progression of these malignancies, often acting in synergy with other epigenetic alterations. It also contributes to the acquisition of drug resistance. In this review, we summarize the role of DNA methylation in hematological malignancies described in the current literature. We discuss in detail the dual role of DNA methylation in normal and aberrant hematopoiesis, as well as the involvement of this type of epigenetic change in other aspects of the disease. Finally, we present a comprehensive overview of the main clinical implications, including a discussion of the therapeutic strategies that regulate or reverse aberrant DNA methylation patterns in hematological malignancies, including their combination with (chemo)immunotherapy. Epigenetic regulation of cell development and fate is a very complex and intricate process. Here, we address in detail the role of DNA methylation remodelers in hematological malignancies and their relationship with other epigenetic effectors. We include a critical discussion of available therapies and their clinical implications for these types of neoplasms, including the combination of hypomethylating and immunotherapy agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|